Shares of Sorrento Therapeutics Inc. (SRNE) are rising over 11% in pre-market today, after the company announced that an Application for Emergency Use Authorization or EUA is under review at the U.S. FDA for its COVI-TRACKTM in vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus.
from RTT - Before the Bell https://ift.tt/37na2Uf
via IFTTT
No comments:
Post a Comment